|
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical research trials and A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis clinical trial. Participants frequently get the best healthcare available for their A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis  A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
For Condition: Multiple Sclerosis
Status: Terminated
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion - relapsing-remitting MS - at least 1 exacerbation in preceding 2 years - at least 1 MRI lesion - stable for 2 months prior to dosing Exclusion - progressive MS - currently treated with an immunomodulatory therapy - previously treated with an approved MS drug where treatment was discontinued for lack of efficacy - active bacterial or viral infections
Total Enrollment:
Location and Contact Information:
Local Institution
New York City, New York,
United States
Local Institution
Dallas, Texas,
United States
Local Institution
Madison, Wisconsin,
United States
Local Institution
New Haven, Connecticut,
United States
Local Institution
Worcester, Massachusetts,
United States
Local Institution
Louisville, Kentucky,
United States
Local Institution
Newark, New Jersey,
United States
Local Institution
Philadelphia, Pennsylvania,
United States
Local Institution
Charlotte, North Carolina,
United States
Local Institution
Burlington, Vermont,
United States
Additional Information:
Study ID Numbers: IM101-200;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035529
Other Multiple Sclerosis Studies:
1. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
2. Safety and Efficacy study of Oral Fampridine-SR on Walking Ability in Multiple Sclerosis
3. Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
4. Assessment of Patients with Multiple Sclerosis (MS)
5. Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
Related Studies:
Other Multiple Sclerosis Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
|
|
|
|
|
|
|
|
